Primary platinum refractory disease

Author: crwz

August undefined, 2024

WebAbstract. Purpose: In general, 50 % up to 80 % of metastasized germ cell tumor patients can be cured by platinum-based chemotherapy. However, 3-5 % of patients will still die of … Web19 hours ago · In the population with platinum-refractory disease, the TIA-GEP score was balanced between arms; however, in the population with platinum-eligible disease, there …

Clinical Situation: Platinum-Resistant/Refractory Recurrence

WebJan 30, 2024 · Patients with more than three prior lines were ineligible on the basis of lower activity seen in more heavily pretreated patients as part of the expansion cohort of the … WebThe subgroup of patients without primary platinum-refractory disease and with 1-3 prior lines of therapy (“phase 3 population”) comprised 137 patients, of whom 46 received NP … excel find total number sum of value

Relacorilant Plus Nab-Paclitaxel Boosts Survival in Platinum …

WebPrior to the advent of PD1/PDL1 checkpoint inhibitors, systemic chemotherapy with cisplatin-based regimens was the standard of care, leading to median survival of around 1 year. 5,6 For patients with platinum-refractory disease, the median survival was only 6–9 months. 7–10 Furthermore, up to 30%–50% of patients with metastatic UC are ineligible … WebJan 25, 2024 · Most in the study had platinum-resistant disease, while 10% in the study arm and 15% in the control arm had primary platinum-refractory disease. To enroll, ... WebApr 12, 2024 · Of 184 patients in the platinum-eligible population, 123 were allocated to the combination and 61 to nivolumab. The primary endpoints were objective response rate … excel find two closest numbers

Solid Tumors PI CRC Protocol #/Title Mechanism Primary In/Ex …

Mirvetuximab Soravtansine Yields Response Benefit in FRα-High …

WebMar 3, 2024 · PIT-565 is under clinical development by Novartis and currently in Phase I for Primary Mediastinal B-Cell Lymphoma. According to GlobalData, Phase I drugs for Primary Mediastinal B-Cell Lymphoma have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how PIT-565’s ... WebMar 14, 2024 · Forty percent of the women had suboptimally resected stage III disease, and 26% had stage IV disease. The primary end point of the study was PFS.[Level of evidence B1] ... Responses have been observed … excel find unused named rangesWebMay 10, 2024 · Patients with primary platinum-refractory ovarian cancer were ineligible, but those with secondary platinum-refractory ovarian cancer could be enrolled. ... 38% had … excel find value and return cell

"WebIn patients with relapsed ovarian cancer, the overall response rates on treatment with topotecan range from 19%-33% in platinum-sensitive patients, 14%-18% in platinum-resistant patients, and 5%-11% in platinum-refractory patients. The proportion of patients achieving stable disease ranges between 17% in refractory and 48% in sensitive patients ... " - Primary platinum refractory disease

Primary platinum refractory disease

Re-challenge of Platinum-based Chemotherapy for Platinum …

WebStandard treatment for ovarian cancer is platinum-based chemotherapy; however, 15% to 30% of patients with ovarian cancer have primary platinum-resistant or refractory … WebJan 23, 2024 · Among the 94 patients with high-grade serous ovarian cancer who received treatment in this study, 11 (12%) had primary platinum-refractory disease, an understudied subpopulation with a substantially worse prognosis. For this reason, as was the case in …

Did you know?

WebJun 2, 2024 · Primary platinum-refractory disease (progression on first-line platinum therapy) or primary platinum resistance (progression < 3 months after completion of first-line platinum therapy) is exclusionary. Pts must have ECOG performance status of 0 or 1, ... WebThe primary endpoint was objective response rate (ORR) and secondary endpoints included disease control rate (DCR), and safety. DNA from tumor biopsies was sequenced to identify biomarkers. Results: The ORR in platinum resistant patients (Cohorts 1--3) was 12.1%, and 6.9% in platinum refractory patients.

WebAug 9, 2024 · In The Lancet Oncology, Radoslav Chekerov and colleagues1 report the results of a randomised phase 2 trial of the efficacy and safety of adding sorafenib (an oral … WebIndeed, treatment options in platinum refractory disease included monochemotherapy with taxanes and methotrexate, ... However, head and neck second malignancies could occurr for impaired immunosurveillance. Recurrent disease with a primary induced resistance to immunotherapy is the result of an incomplete and ineffective first immune response.

WebJul 1, 2024 · Platinum-Refractory Primary Peritoneal Carcinoma; Recent clinical studies. Etiology. HIPEC after neoadjuvant chemotherapy and interval debulking is associated with … WebJan 23, 2024 · Whereas the majority of patients show at least a partial response to these therapies (resulting in median overall survival of 4.3 years [2]), 25% will be platinum-refractory in the primary setting ...

Webpatients with platinum resistant ovarian cancer. Patients with platinum resistant ovarian carcinoma and measurable disease received canfosfamide at 960 mg/m2 in combination with PLD at 50 mg/m2, intravenously day 1 in every 28 day cycles until tumor progression or unacceptable toxicities. The primary endpoints were objective response

WebJul 1, 2007 · Platinum-refractory disease was defined as cancer with documented tumor progression ... Fatal bleeding from the primary site during the treatment period occurred … bryn mawr multi family homesWebOS is improved in patients without primary platinum refractory disease. Intermittent Rel+Nab vs Nab: ORR: 35.7 vs 35.8% PFS: 5.6 vs 3.8 months* ... Promising activity of … excel find value based on column and rowWebMar 31, 2024 · To date, there are no validated predictive markers of primary platinum refractory or resistant disease. Although limited and biologically unfounded, the time since the last platinum chemotherapy currently defines resistance (≤ 6 months) or sensitivity (> 6 months) to the treatment in HGSOC patients that experience recurrent disease [25, 26]. excel find value and return row numberWebDec 4, 2024 · The mean number of prior lines of chemotherapy was 1.3 which mean almost all of had primary platinum-refractory diseases. Median treatment duration was 4.3 months (1.1~16.1). bryn mawr neighborhoodWebMay 1, 2024 · Ovarian cancer has poor survival rates due to a combination of diagnosis at advanced disease stages and disease recurrence as a result of platinum chemotherapy … excel find value based on two columnsWebrefractory disease, while more than 6 month of PFI is defining of a platinum sensitive relapse [8,9]. This GCIG definition permits CT/PET imaging to evaluate rising CA-125 … excel find value between two charactersWebOct 26, 2024 · If patients had primary platinum-refractory disease or primary platinum resistance, a histologically confirmed diagnosis of epithelial ovarian carcinoma with … bryn mawr neighborhood association